🔎 Trials Near Me

Beranda › Kanker Paru Non-Sel Kecil › Pennsylvania › York

Uji klinis Kanker Paru Non-Sel Kecil di York, PA

15 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar York (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Menerima pesertaFase 3
  • WellSpan Health-York Cancer Center, York
  • WellSpan Health-York Hospital, York
  • UPMC Memorial, York
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT04267848

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Menerima pesertaFase 1/2
  • WellSpan York Cancer Center, York
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04585750

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Menerima pesertaFase 3
  • WellSpan Oncology Research, York
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07361510

Pan-tumor MRD Study

Menerima pesertaStudi observasional
  • Cancer Care Associates of York (CCAY), York
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06605404

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Menerima pesertaFase 3
  • Research Site, York
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06692738

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Menerima pesertaStudi observasional
  • WellSpan Medical Oncology & Hematology at York Cancer Center, York
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05059444

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Menerima pesertaFase 2
  • WellSpan Health-York Cancer Center, York
  • UPMC Memorial, York
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Menerima pesertaFase 2
  • Cancer Care Associates of York, York
  • WellSpan Health-York Cancer Center, York
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Menerima pesertaFase 2
  • Cancer Care Associates of York, York
  • WellSpan Health-York Cancer Center, York
  • WellSpan Health-York Hospital, York
18 Minutes · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06031688

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Menerima pesertaStudi observasional
  • WellSpan Health - York Cancer Center, York
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT06418204

GEMINI-NSCLC: NSCLC Biomarker Study

Menerima pesertaStudi observasional
  • Cancer Care Associates of York, York
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Feb 2026 · NCT05236114

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Menerima pesertaFase 1/2
  • Cancer Care Associates of York (site 206), York
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 11 Des 2025 · NCT03556228

Uji klinis Kanker Paru Non-Sel Kecil di kota lain

Studi lain di York

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.